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published NMAs have accounted for this variable when assessing the relative 
efficacy of CHB interventions. We undertook baseline-adjusted and -unadjusted 
analyses using the same dataset to explore the impact of BVL on UVL 
achievement. METHODS: The NMA was undertaken in WinBUGs using standard 
fixed/random effects approaches. A systematic literature review was the source 
of efficacy data for eight interventions. Individual patient data from an entecavir 
RCT was used to quantify the impact of different baseline characteristics on the 
likelihood of achieving UVL at one year. Study level mean baseline values from 
all identified papers and the results from the abovementioned analysis were 
used to inform prior distributions in the adjusted analysis. Results were 
presented as relative risks (RRs) at one year and 95% credible intervals. Entecavir 
was the reference treatment. Sensitivity analyses surrounding the 
inclusion/exclusion of individual studies were performed. RESULTS: Entecavir 
and tenofovir studies included heterogeneous patient populations in terms of 
BVL (mean entecavir value 9.29 log10copies/ml, tenofovir value 8.65 
log10copies/ml). After adjusting the UVL for baseline viral load using an 
informative prior, the RR for entecavir versus tenofovir went from statistically 
significant to non-significant [unadjusted: RR 1.43 (1.30 to 1.54), adjusted: RR 1.21 
(0.48 to 1.51)]. Relative efficacy results for all other interventions were similar 
across adjusted and unadjusted analyses. Adjusted results were robust to the 
inclusion/exclusion of additional studies. Adjusted results for all interventions 
were consistent with clinical trial data. CONCLUSIONS: Adjusted and unadjusted 
NMA, using the same dataset, demonstrated the importance of adjusting for BVL 
when assessing the relative efficacy of CHB interventions. Failing to account for 
differences in BVL across studies may result in flawed relative efficacy estimates.  
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OBJECTIVES: In absence of head-to-head trials and over hundred new molecules 
in clinical development for hepatitis C virus (HCV) infection, mixed treatment 
comparisons continue to play a crucial role in guiding clinical decision making. 
This study was aimed to identify the practical challenges of conducting mixed 
treatment comparisons in chronic HCV genotype-1 patients, especially in 
subgroups with clinical factors that are associated with poor treatment response 
and/or increased risks. METHODS: A systematic review was conducted to 
identify randomized controlled trials of telaprevir (TVR) and boceprevir (BOC) in 
HCV genotype-1 patient population. Included clinical trials were assessed to 
check: 1) if clinical factors related to poor treatment response (race, prior viral 
load, grade of underlying cirrhosis/fibrosis) were reported and subgroup analyses 
were conducted; and 2) if important safety endpoints (rash, anemia, 
neutropenia) were reported with a clear definition of the gradient of severity. 
RESULTS: A total of eight trials were identified: five in treatment-naïve patients 
(4TVR, 1BOC) and three in treatment-experienced patients (2TVR, 1BOC). Among 
the seven trials which reported the proportion of African Americans and 
information on grade of fibrosis, two did not conduct subgroup analyses 
accordingly. Of the trials reporting prior viral load (8) and cirrhosis (5), only three 
and two trials presented related subgroup analyses, respectively. Severity of 
important safety endpoints such as rash and anemia was not defined in four of 
the studies (50%), mainly telaprevir trials, and neutropenia was not defined in 
almost two-thirds (5/8). CONCLUSIONS: From an already small pool of studies to 
begin with, unavailability of data and lack of safety endpoint definitions are 
challenges that may reduce the feasibility and increase potential biases for 
conducting mixed treatment comparisons. Overcoming these identified 
challenges will improve understanding of the comparative efficacy and safety of 
HCV drugs, particularly in the at-risk population.  
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OBJECTIVES: This study aimed to assess the association of Crohn’s disease 
prevalence with demographic characteristics in the U.S. veteran population. 
METHODS: This study analyzed a patient sample from the Veterans Health 
Administration (VHA) Medical SAS datasets from October 1, 2005 to May 31, 2012. 
All patients diagnosed with Crohn’s disease during 2011 were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 555. Patients with medical benefits enrollment not covering 
2011 were excluded. Study patient demographic information was then captured 
and categorized into groups. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: For VHA patients diagnosed in 2011 with 
Crohn’s disease (N=41,418), prevalence varied by race as follows: Non-Hispanic 
White (0.23%), Non-Hispanic Black (0.14%), Hispanic (0.09%) and other races 
(0.13%). When stratified by age, the highest prevalence was observed in the 
higher age groups: 55-64 (0.21%), 35-54 (0.20%), and 65+ (0.17%). Based on the 
examination of Crohn’s disease prevalence in different states, the disease was 
found to be most likely diagnosed in Maine (0.35%), Vermont (0.29%), Connecticut 
(0.28%) and New Hampshire (0.24%). On the contrary, Puerto Rico (0.07%), 
Washington D.C. (0.07%) and Hawaii (0.06%) showed the lowest prevalence. 
However, the difference was never greater than 0.3%. CONCLUSIONS: The 
uneven distribution of Crohn’s disease among U.S. states suggests a geographic 
variation in risk areas that may be useful for future targeted intervention 
strategies. Further research may be necessary for middle-aged and elderly 
patient groups to prevent this disease.  
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OBJECTIVES: To estimate pharmacy and overall budgetary impact of introducing 
linaclotide to a hypothetical one-million-member managed care plan. 
METHODS: A decision-tree model (one-year time horizon) was constructed to 
estimate the budgetary impact of linaclotide. Model inputs include plan 
population, treatment costs, estimated current and future monthly prescription 
utilization, response rates, and potential medical cost offsets. Model outputs are 
per-member per-month (PMPM) pharmacy and medical costs. Treatment options 
include linaclotide, lubiprostone, and other prescription therapies. The 
proportion of patients who respond to linaclotide are assumed to incur lower 
health care costs due to less health care utilization. Treatment costs are based 
on published prices (polyethylene glycol, the most common prescription therapy 
is used as a surrogate for other generically-available prescription therapies). 
Daily net treatment costs (payer perspective) are $5.50, $6.37, and $0.29 for 
linaclotide, lubiprostone, and polyethylene glycol, respectively. Current 
prescription utilization (14% lubiprostone, 86% other therapies) and potential 
annual per-patient medical cost offsets (IBS-C: $1781, CC: $2002) are derived from 
retrospective database analyses; future prescription utilization (8% linaclotide, 
10% lubiprostone, 82% other) is assumed. Linaclotide response rates (IBS-C: 
33.6%, CC: 18.6%) are from primary endpoints of Phase III clinical trials. 
Budgetary impact is calculated as the cost difference between current and future 
scenarios. One-way sensitivity analyses were performed. RESULTS: Introducing 
linaclotide to a managed care formulary is estimated to increase the pharmacy 
budget by $0.007 PMPM; when potential medical cost offsets are included, the 
resulting overall budgetary impact is estimated to be $0.003 PMPM. In sensitivity 
analyses, number of linaclotide patients, IBS-C cost offsets, and conversion from 
other therapies to linaclotide had the greatest influence on budgetary impact; 
however, results did not vary substantially from base-case. CONCLUSIONS: 
Linaclotide is expected to result in a slight increase in pharmacy budgets which 
may be partially offset by medical cost savings.  
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OBJECTIVES: Hepatitis C virus (HCV) infection is a chronic disease affecting the 
liver that may lead to cirrhosis and result in costly outcomes including ascites, 
variceal bleeds, encephalopathy, hepatocellular carcinoma (HCC), and liver 
transplant. The purpose of this study is to evaluate the overall cost burden of 
genotype 1 chronic HCV patients treated with current triple therapy regimens 
(protease inhibitor/peginterferon alfa/ribavirin) or future quadruple therapy 
regimens (polymerase or NS5A inhibitor/protease inhibitor/peginterferon 
alfa/ribavirin), and the incremental cost burden of patients identified as having 
chronic HCV by new screening guidelines. METHODS: A 50-year Markov cohort 
model was developed to compare current and future HCV treatment regimens. 
Patients who achieved sustained virologic response (SVR) were considered 
responders and were assigned a decreased level of progression to HCC, liver 
transplant, and liver-related mortality. Cost inputs, including pharmacy and 
medical costs associated with progressive HCV-related liver disease, were 
derived from published sources and Redbook. Treatment effectiveness, 
adherence rates, and transition probabilities for responders and non-responders 
were derived from published sources. SVR for quadruple therapy was derived 
from interim phase II trial results. Cost and outcomes were discounted at 3% and 
tested with a one-way sensitivity analysis. RESULTS: The discounted cost to 
treat a patient with triple therapy is US$150,790, including pharmacy costs and 
hepatic sequelae. Assuming treatment at time of drug approval, the 
corresponding discounted cost for quadruple therapy is projected at US$205,045 
per patient. Based on proposed screening guidelines, approximately 150,000 
additional chronic HCV patients will be both diagnosed and treated. The 
incremental discounted cost of treating these additional patients with quadruple 
therapy is projected to be $28.5 billion and is due in part to increased patient 
lifespan. CONCLUSIONS: New screening guidelines and therapeutic advances are 
projected to improve patient utilization of more effective treatments and result 
in an increased level of health care spending.  
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OBJECTIVES: To assess the clinical and economic burden of gastroesophageal 
reflux disease (GERD) in the U.S. veteran population. METHODS: Patients 
diagnosed with GERD (International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] codes: 309.81, 530.1, 530.10-530.12, 530.81, 787.1) 
were included in a retrospective study (1/1/2006-5/31/2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Continuous 
medical and pharmacy benefits were required 12-month pre- and 12-month 
post-index date (initial GERD diagnosis date). Comorbidities were examined for 
the 12 months baseline period; medication and treatment were examined during 
the 60-day follow-up period. Health care resource utilization and costs were 
assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: A total of 
1,123,133 GERD patients were identified in the database. During the 12-month 
baseline period, the most common comorbidities were unspecified essential 
hypertension (23.92%), diabetes (13.70%) and hyperlipidemia (8.36%). During the 
60 days post-index date, the most commonly prescribed medications were 
omeprazole (39.87%), simvastatin (27.52%), lisinopril (19.11%), ranitidine 
hydrochloride (12.48%), and hydrochlorothiazide (10.30%). During the 12-month 
follow-up period, percentages of inpatient (16.40%), emergency room (ER) 
(20.66%), physician office (99.83%), and outpatient visits (99.86%) were also 
calculated. Patient expenditures were found to be $5,498 (SD=$32,411) for 
inpatient, $246 (SD=$899) for ER, $6,724 (SD=$10,694) for physician office and 
$7,201 (SD=$11,407) for outpatient visits. CONCLUSIONS: Results suggest that 
omeprazole is the most frequently prescribed medication after a GERD diagnosis. 
GERD was associated with a high inpatient admission and ER visit rates, which 
translated into a significant cost burden for the health care system.  
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OBJECTIVES: To evaluate total annual all-cause costs of chronic constipation 
(CC) among patients with different health plan benefit designs and assess 
incremental costs of CC in a commercially insured population. METHODS: 
Patients were identified from the HealthCore Integrated Research Database as 
follows: (1) age ≥18 years as of January 1, 2010; (2) continuous eligibility in 2010; 
(3) ≥2 constipation diagnoses (ICD-9-CM: 564.0x) occurring ≥90 days apart or ≥1 
constipation diagnosis plus ≥1 constipation-related prescription occurring ≥90 
days apart. A control group without irritable bowel syndrome, constipation, 
abdominal pain, or bloating was randomly selected using 1:1 matching on basic 
demographic characteristics. Patients were categorized by health plan benefit 
design into non-capitated health maintenance organizations (HMO), preferred 
provider organizations (PPO), Medicare Advantage (MA), and other benefit 
designs. Total all-cause health care costs included pharmacy costs and costs 
from medical services. Generalized linear models were used to evaluate the 
incremental costs attributable to CC. RESULTS: Of 14,854 CC patients and 
controls identified, 71.7% had PPO, 12.0% had non-capitated HMO, 10.2% had MA, 
and 6.1% had other benefit designs. Mean age (±SD) was 58.7 (±20.4) years; 75.4% 
were female. Overall, CC patients had $8,713 (P<0.001) higher unadjusted total 
annual all-cause health care costs versus matched controls; costs were $9,736 
(P<0.001) higher for non-capitated HMO, $8,029 (P<0.001) for PPO, and $11,813 
(P<0.001) for MA. Medical costs were the primary driver of unadjusted all-cause 
costs regardless of benefit design (82%-84% of total costs). This finding remained 
consistent in the overall study population even after adjusting for demographics 
and comorbidities. Total incremental all-cause costs associated with CC were 
$3,508 (P<0.001), with 81% for medical services. CONCLUSIONS: The economic 
burden of CC is substantial in a US commercially insured population. A 
consistent burden was seen across different health plan benefit designs, with 
costs driven by the use of medical services.  
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OBJECTIVES: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that 
results from chronic inflammation restricted to all or part of the colon and 
begins in the rectum. UC significantly impact quality of life and accounts for 
substantial costs to the health care system and society. The objective of this 
study was to describe and estimate health care resource utilization in the 
treatment of UC from a health care system perspective. METHODS: A 
retrospective study of the Quebec provincial drug reimbursement program 
(RAMQ) was conducted using a randomly selected group of patients who 
received at least one diagnosis of UC (ICD-9=556.x) between January 1st, 2010 and 
December 31st, 2011, but who did not received a diagnosis of Crohn’s disease 
(ICD-9=555.x). A control group of patients without any diagnosis of UC was 
created on a 1:1 ratio and matched for age and gender. The difference between 
the costs of resources consumed during the 2year study period by the two groups 
(using t-test) provided an estimate of the incremental cost associated with the 
management of UC. RESULTS: A total of 2,975 patients with UC were included in 
the study (mean age=55.5 years, 52% females). During the 2-year study period, 
patients had received a total of 57,264 scripts for anti-inflammatory drugs, 
immunosuppressors and/or anti-TNFα agents. The total cost of medical 
procedures, medications and hospitalizations were higher for UC patients, with 
an annual incremental cost per patient of CAN$370 (95%CI: 331-410), CAN$2,374 
(95%CI: 2135-2613) and CAN$2,795 (95%CI: 2399-3192), respectively. The annual 
difference in direct costs between UC patients and controls was estimated at 
CAN$5,539 (95%CI: 5,036-6,043) per patient. CONCLUSIONS: The present analysis 
illustrates the high cost of treatments, the high frequency of hospitalizations 
resulting in increased hospitalization costs and the substantial economic 
burden, in terms of direct medical costs associated with UC.  
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OBJECTIVES: Antiemetic is a drug that is effective against vomiting and nausea. 
The objective of this study is to calculate price trends for individual antiemetic 
and to describe the trends of utilization and spending on antiemetic drugs in the 
U.S. Medicaid program. METHODS: A retrospective descriptive analysis was 
performed using data from the Medicaid database from 1991 through second 
quarter 2011. We extracted the utilization and expenditure data from the 
national Medicaid pharmacy files collected by the Centers for Medicare & 
Medicaid Services. Study drugs include antihistamines (cyclizine, 
dimenhydrinate, buclizine), steroids (dexamethasone, methylprednisolone), 
dopamine antagonists (droperidol, ondansetron, granisetron, palonosetron). 
Total prescriptions reimbursed by Medicaid and total reimbursement cost were 
calculated by adding the data for each antiemetic identified by its NDC. The 
Annual totals of reimbursement per-prescription were calculated as annual total 
reimbursement divided by Annual total number of prescriptions. RESULTS: The 
total number of prescriptions which paid by Medicaid was increased from 
$339,822 in 1991 to $1.0 million in second quarter of 2011. The data shows 80% 
decrease in antiemetic utilization in 1999. The drug Ondansetron has increasing 
trends after 2006 up to about 70% in the first quarter of 2011. The price was in 
increasing rate until 2011. About 100% increase in the price of generic Zofran. 
The average of reimbursement per prescription has increased from $15.22 in 
1991 to $36.90 in 2011. CONCLUSIONS: In the light of this study, more studies are 
needed to create antiemetic guidelines that would help to improve efficacy, 
increase the patients compliance, and decrease the antiemetic costs.  
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OBJECTIVES: To evaluate the cost-effectiveness of linaclotide 290 mcg once daily 
versus lubiprostone 8 mcg twice daily in the treatment of adult patients with 
irritable bowel syndrome with constipation (IBS-C) METHODS: Using model 
inputs derived from published literature, linaclotide Phase III trial data, and a 
physician survey on resource utilization associated with treatment failure, a 
decision-tree model was constructed to estimate outcomes and costs of 
treatment for IBS-C. Response to therapy was defined as (1) a ≥14-point increase 
from baseline in IBS-QOL overall score at Week 12 or (2) one of the top two 
responses (moderately/significantly relieved) on a seven-point IBS symptom 
relief question in ≥2 of 3 months. Patients who do not respond to therapy are 
assumed to fail therapy and accrue costs associated with a treatment failure. 
Model time horizon is aligned with clinical trial duration at 12 weeks. Model 
outputs include number of responders, quality-adjusted life-years (QALYs), total 
costs (including direct and indirect), and incremental cost-effectiveness ratios 
(ICERs). Both one-way and probabilistic sensitivity analyses were conducted. 
RESULTS: Treatment for IBS-C with linaclotide produced more responders than 
lubiprostone for both response definitions (19.3% vs. 13.0% and 61.6% vs. 57.2% 
for IBS-QOL and symptom relief, respectively), lower per-patient costs ($780 vs. 
$870 and $1,014 vs. $1,088), and higher QALYs (0.1924 vs. 0.1917 and 0.1909 vs. 
0.1894, over the 12-week time horizon). Therefore, linaclotide was dominant 
(more effective and less expensive) compared to lubiprostone. Results were 
similar to base-case for most one-way sensitivity analyses. The majority of 1,000 
second order Monte Carlo simulations resulted in linaclotide dominant ICERs for 
both definitions of treatment response. CONCLUSIONS: Linaclotide was found to 
be cost-effective versus lubiprostone for treatment of adult patients with IBS-C.  
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OBJECTIVES: To assess the cost-effectiveness of infliximab as induction therapy 
(3 doses) for the treatment of severe active ulcerative colitis, i.e. exacerbations 
requiring hospitalization in adult patients with an inadequate response to 
conventional therapy including intravenous glucocorticoids, compared with 
surgery (colectomy) in Poland. METHODS: This study used the decision tree 
model which was positively received by NICE and adjusted to Polish settings. 
